Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases ...

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference ...

Scotiabank lowered the firm’s price target on Apellis (APLS) to $30 from $35 and keeps a Sector Perform rating on the shares. The company ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported Q3 Syfovre revenues that came in below expectations.

Wells Fargo lowered the firm’s price target on Apellis (APLS) to $30 from $43 and keeps an Equal Weight rating on the shares. The firm thinks Q3 was validating for its view of a slowing GA ...

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it down for ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from two ...